Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

PET Imaging of Dll4 Expression in Glioblastoma and Colorectal Cancer Xenografts Using (64)Cu-Labeled Monoclonal Antibody 61B.

Zhou B, Wang H, Liu R, Wang M, Deng H, Giglio BC, Gill PS, Shan H, Li Z.

Mol Pharm. 2015 Oct 5;12(10):3527-34. doi: 10.1021/acs.molpharmaceut.5b00105. Epub 2015 Aug 28.

2.

Targeting Acidity in Pancreatic Adenocarcinoma: Multispectral Optoacoustic Tomography Detects pH-Low Insertion Peptide Probes In Vivo.

Kimbrough CW, Khanal A, Zeiderman M, Khanal BR, Burton NC, McMasters KM, Vickers SM, Grizzle WE, McNally LR.

Clin Cancer Res. 2015 Oct 15;21(20):4576-85. doi: 10.1158/1078-0432.CCR-15-0314. Epub 2015 Jun 29.

3.

Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe.

Phillips E, Penate-Medina O, Zanzonico PB, Carvajal RD, Mohan P, Ye Y, Humm J, Gönen M, Kalaigian H, Schöder H, Strauss HW, Larson SM, Wiesner U, Bradbury MS.

Sci Transl Med. 2014 Oct 29;6(260):260ra149. doi: 10.1126/scitranslmed.3009524. Epub 2014 Oct 29.

4.

Biological evaluation of 131I- and CF750-labeled Dmab(scFv)-Fc antibodies for xenograft imaging of CD25-positive tumors.

Fan Q, Cai H, Yang H, Li L, Yuan C, Lu X, Wan L.

Biomed Res Int. 2014;2014:459676. doi: 10.1155/2014/459676. Epub 2014 Apr 27.

5.

Automated tracking of quantitative assessments of tumor burden in clinical trials.

Rubin DL, Willrett D, O'Connor MJ, Hage C, Kurtz C, Moreira DA.

Transl Oncol. 2014 Feb 1;7(1):23-35. eCollection 2014 Feb.

6.

Molecular imaging for cancer diagnosis and surgery.

Hussain T, Nguyen QT.

Adv Drug Deliv Rev. 2014 Feb;66:90-100. doi: 10.1016/j.addr.2013.09.007. Epub 2013 Sep 22. Review.

7.

Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts.

Strand J, Honarvar H, Perols A, Orlova A, Selvaraju RK, Karlström AE, Tolmachev V.

PLoS One. 2013 Aug 1;8(8):e70028. doi: 10.1371/journal.pone.0070028. Print 2013.

8.

Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.

Alcorn S, Walker AJ, Gandhi N, Narang A, Wild AT, Hales RK, Herman JM, Song DY, Deweese TL, Antonarakis ES, Tran PT.

Int J Mol Sci. 2013 Jul 16;14(7):14800-32. doi: 10.3390/ijms140714800. Review.

9.

Nanotheranostics for personalized medicine.

Kim TH, Lee S, Chen X.

Expert Rev Mol Diagn. 2013 Apr;13(3):257-69. doi: 10.1586/erm.13.15. Review.

10.

Synthesis and characterization of anti-EGFR fluorescent nanoparticles for optical molecular imaging.

Chan LW, Wang YN, Lin LY, Upton MP, Hwang JH, Pun SH.

Bioconjug Chem. 2013 Feb 20;24(2):167-75. doi: 10.1021/bc300355y. Epub 2013 Jan 10.

11.

Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring.

Li D, Liu S, Liu R, Park R, Hughes L, Krasnoperov V, Gill PS, Li Z, Shan H, Conti PS.

Mol Pharm. 2013 Jan 7;10(1):329-36. doi: 10.1021/mp300461b. Epub 2012 Dec 18.

12.

Molecular Imaging Probe Development using Microfluidics.

Liu K, Wang MW, Lin WY, Phung DL, Girgis MD, Wu AM, Tomlinson JS, Shen CK.

Curr Org Synth. 2011 Aug 1;8(4):473-487.

13.

Molecular imaging probe development: a chemistry perspective.

Nolting DD, Nickels ML, Guo N, Pham W.

Am J Nucl Med Mol Imaging. 2012 Jul 10;2(3):273-306.

14.

Fusion of [(18)F]FDG PET with fluorescence diffuse optical tomography to improve validation of probes and tumor imaging.

Garofalakis A, Dubois A, Thézé B, Czarny B, Tavitian B, Ducongé F.

Mol Imaging Biol. 2013 Jun;15(3):316-25. doi: 10.1007/s11307-012-0581-z.

15.

Early experiences in establishing a regional quantitative imaging network for PET/CT clinical trials.

Doot RK, Thompson T, Greer BE, Allberg KC, Linden HM, Mankoff DA, Kinahan PE.

Magn Reson Imaging. 2012 Nov;30(9):1291-300. doi: 10.1016/j.mri.2012.06.002. Epub 2012 Jul 15.

16.

Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.

Waerzeggers Y, Ullrich RT, Monfared P, Viel T, Weckesser M, Stummer W, Schober O, Winkeler A, Jacobs AH.

Br J Radiol. 2011 Dec;84 Spec No 2:S179-95. doi: 10.1259/bjr/76389842. Review.

17.

Advances in molecular imaging for breast cancer detection and characterization.

Specht JM, Mankoff DA.

Breast Cancer Res. 2012 Mar 16;14(2):206. Review.

18.

FRET enhanced fluorescent nanodiamonds.

Fudala R, Raut S, Maliwal BP, Zerda TW, Gryczynski I, Simanek E, Borejdo J, Rich R, Akopova I, Gryczynski Z.

Curr Pharm Biotechnol. 2014;14(13):1127-33.

19.

The clinical significance and management of lesion motion due to respiration during PET/CT scanning.

Callahan J, Kron T, Schneider-Kolsky M, Hicks RJ.

Cancer Imaging. 2011 Dec 28;11:224-36. doi: 10.1102/1470-7330.2011.0031. Review.

20.

Recent trends in antibody-based oncologic imaging.

Kaur S, Venktaraman G, Jain M, Senapati S, Garg PK, Batra SK.

Cancer Lett. 2012 Feb 28;315(2):97-111. doi: 10.1016/j.canlet.2011.10.017. Epub 2011 Oct 20. Review.

Supplemental Content

Support Center